Orion Portfolio Solutions LLC Grows Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Orion Portfolio Solutions LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.7% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 90,026 shares of the biopharmaceutical company's stock after acquiring an additional 3,224 shares during the period. Orion Portfolio Solutions LLC's holdings in Gilead Sciences were worth $8,316,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in Gilead Sciences during the fourth quarter valued at approximately $29,000. Crews Bank & Trust bought a new stake in Gilead Sciences in the fourth quarter worth $31,000. Finally, Stephens Consulting LLC lifted its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $97.22, for a total transaction of $13,822,739.60. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company's stock, valued at $12,626,253.06. The trade was a 52.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 302,785 shares of company stock worth $30,503,250. 0.16% of the stock is owned by insiders.

Remove Ads

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock traded down $0.78 during trading on Tuesday, hitting $111.27. 3,754,412 shares of the company's stock traded hands, compared to its average volume of 7,279,950. The business has a 50-day simple moving average of $105.88 and a 200-day simple moving average of $95.20. The stock has a market capitalization of $138.57 billion, a P/E ratio of 299.91, a PEG ratio of 0.71 and a beta of 0.21. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a $0.79 dividend. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences's dividend payout ratio (DPR) is currently 854.05%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on GILD shares. BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Needham & Company LLC reissued a "hold" rating on shares of Gilead Sciences in a report on Wednesday, February 12th. Finally, Bank of America upped their price target on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Eleven analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.